02451nas a2200253   4500008003900000245012000039210006900159260000800228300000800236490000700244520173200251100001701983700002102000700001502021700001302036700001502049700001402064700001502078700001602093700001402109700001402123700001502137856004502152       2004                          d00aFatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients0 aFatal disseminated Kaposis sarcoma following human herpesvirus 8  cFeb  a2950 v103 aHuman herpesvirus 8 (HHV-8) is associated with the development of Kaposi's sarcoma (KS) and rare lymphoproliferative disorders in immunosuppressed patients. The risk of HHV-8 transmission by liver transplantation and the clinical manifestations of primary infection in this setting have yet to be determined. In order to evaluate this risk, we measured the seroprevalence of HHV-8 among 122 liver donors and their respective recipients before and after transplantation. Molecular methods and immunohistochemical analyses were performed to study the features of HHV-8 infection. Antibodies to HHV-8 were detected in sera of 4 donors before transplantation (3.3%) and of 3 recipients (2.4%). None of the 3 recipients, who were HHV-8 seropositive before transplantation, developed a KS during the follow-up. Four primary HHV-8 infections were detected among the 4 HHV-8 seronegative recipients who received a liver from an HHV-8 positive donor. Among these 4 recipients, 2 particularly immunosuppressed patients developed symptomatic diseases and died a few months after transplantation, harboring disseminated KS and HHV-8 positive lymphoproliferation. In these 2 patients, HHV-8 DNA genome sequences were detectable in peripheral blood mononuclear cells and other tissues with high viremia levels before and at the beginning of HHV-8-related diseases. In conclusion, in liver transplantation recipients, HHV-8 primary infection can be associated with fatal outcome. This study raises the question of screening liver donors for HHV-8--even in low HHV-8 infection prevalence countries--not systematically to exclude the graft but to monitor, clinically and biologically, patients who received a graft from an HHV-8-infected donor.1 aMarcelin, AG1 aRoque-Afonso, AM1 aHurtova, M1 aDupin, N1 aTulliez, M1 aSebagh, M1 aArkoub, ZA1 aGuettier, C1 aSamuel, D1 aCalvez, V1 aDussaix, E  uhttps://notifylibrary.org/reference/4769